A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Clinical trial NCT01903993 · COMPLETED
Trial details
- NCT number
- NCT01903993
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-06
- Primary completion
- 2015-11-19
- Enrollment
- 287
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.